Boudes Pol F
Insider CIK 1454771 · PLX Director · CYMA Chief Medical Officer · GALT Chief Medical Officer · FOLD Chief Medical Officer
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| PLX Protalix BioTherapeutics, | A Award deriv | 2026-09-03 | 2026-09-04 | 8,500 | — | $0 | 8,500 | SEC↗ |
| PLX Protalix BioTherapeutics, | A Award deriv | 2026-09-03 | 2026-09-04 | 17,000 | — | $0 | 17,000 | SEC↗ |
| PLX Protalix BioTherapeutics, | A Award deriv | 2026-09-03 | 2026-09-04 | 8,500 | — | $0 | 8,500 | SEC↗ |
| PLX Protalix BioTherapeutics, | A Award deriv | 2026-09-03 | 2026-09-04 | 17,000 | — | $0 | 17,000 | SEC↗ |
| PLX Protalix BioTherapeutics, | A Award deriv | 2025-09-03 | 2025-09-04 | 15,000 | — | $0 | 15,000 | SEC↗ |
| PLX Protalix BioTherapeutics, | A Award | 2025-09-03 | 2025-09-04 | 7,500 | — | $0 | 7,500 | SEC↗ |
| GALT GALECTIN THERAPEUTICS INC | A Award deriv | 2024-01-24 | 2024-02-07 | 65,000 | — | $0 | 65,000 | SEC↗ |
| GALT GALECTIN THERAPEUTICS INC | A Award deriv | 2024-01-24 | 2024-02-07 | 40,000 | — | $0 | 40,000 | SEC↗ |
| PLX Protalix BioTherapeutics, | A Award deriv | 2023-09-29 | 2023-10-03 | 61,676 | — | $0 | 61,676 | SEC↗ |
| GALT GALECTIN THERAPEUTICS INC | A Award deriv | 2023-01-26 | 2023-01-30 | 50,000 | — | $0 | 50,000 | SEC↗ |
| PLX Protalix BioTherapeutics, | A Award deriv | 2022-09-07 | 2022-09-09 | 50,000 | — | $0 | 50,000 | SEC↗ |
| GALT GALECTIN THERAPEUTICS INC | A Award deriv | 2022-01-24 | 2022-01-25 | 50,000 | — | $0 | 50,000 | SEC↗ |
| GALT GALECTIN THERAPEUTICS INC | A Award deriv | 2021-03-25 | 2021-03-29 | 50,000 | — | $0 | 50,000 | SEC↗ |
| GALT GALECTIN THERAPEUTICS INC | A Award deriv | 2021-03-25 | 2021-03-29 | 100,000 | — | $0 | 100,000 | SEC↗ |
| GALT GALECTIN THERAPEUTICS INC | A Award deriv | 2020-03-12 | 2020-03-16 | 300,000 | — | $0 | 300,000 | SEC↗ |
| PLX Protalix BioTherapeutics, | A Award deriv | 2020-01-20 | 2020-01-22 | 40,000 | — | $0 | 40,000 | SEC↗ |
| CBAY CymaBay Therapeutics, Inc. | A Award deriv | 2019-01-29 | 2019-01-31 | 138,312 | — | $0 | 138,312 | SEC↗ |
| CBAY CymaBay Therapeutics, Inc. | A Award deriv | 2018-01-24 | 2018-01-26 | 125,000 | — | $0 | 125,000 | SEC↗ |
| CBAY CymaBay Therapeutics, Inc. | A Award deriv | 2017-01-19 | 2017-01-23 | 100,000 | — | $0 | 100,000 | SEC↗ |
| CBAY CymaBay Therapeutics, Inc. | A Award deriv | 2017-01-04 | 2017-01-06 | 21,000 | — | $0 | 42,000 | SEC↗ |
| CBAY CymaBay Therapeutics, Inc. | A Award deriv | 2016-12-30 | 2017-01-04 | 21,000 | — | $0 | 21,000 | SEC↗ |
| CBAY CymaBay Therapeutics, Inc. | A Award deriv | 2016-01-26 | 2016-01-28 | 54,000 | — | $0 | 54,000 | SEC↗ |
| CBAY CymaBay Therapeutics, Inc. | A Award deriv | 2015-01-07 | 2015-01-27 | 75,000 | — | $0 | 75,000 | SEC↗ |
| CYMA CymaBay Therapeutics, Inc. | A Award deriv | 2014-04-15 | 2014-04-16 | 77,000 | — | $0 | 77,000 | SEC↗ |
| CYMA CymaBay Therapeutics, Inc. | A Award deriv | 2014-04-15 | 2014-04-16 | 26,000 | — | $0 | 26,000 | SEC↗ |
| FOLD AMICUS THERAPEUTICS INC | A Award deriv | 2012-06-04 | 2012-06-06 | 80,000 | — | $0 | 80,000 | SEC↗ |
| FOLD AMICUS THERAPEUTICS INC | A Award deriv | 2012-02-15 | 2012-02-17 | 60,000 | — | $0 | 60,000 | SEC↗ |